Jointly provided by Partners for Advancing Clinical Education (PACE), the National Eczema Association and Impact Education, LLC.
|
This activity is supported by an independent educational grant from Sanofi and Regeneron Pharmaceuticals, Inc.
|
This CE program is intended for managed care and payer professionals from health plans, PBMs, integrated health systems, and other payer organizations. Others who wish to register may be added to a wait list based on venue capacity.
Please participate in the pre-program survey: Click Here
The program will feature a multidisciplinary panel including a pediatric dermatologist, and California Region managed care/payer experts.
|
|
Who Should Attend?
|
This activity is designed to meet the educational needs of AMCP California affiliate members in the roles of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
|
|
Statement of Need/Program Overview
|
Enhanced knowledge is needed of the overall burden of AD in children and recommended treatments that can empower managed care, specialty pharmacy, and other payer decision makers to implement health care benefit policy strategies that will enhance optimal treatment outcomes. In addition, effective communication and collaboration is needed between payer professionals and pediatric dermatologists for resolving coverage issues, addressing reimbursement concerns, and streamlining administrative processes. Lastly, to address racial and ethnic disparities in children with AD, target audience members need to enact coverage criteria that takes into consideration there are different presentations of AD across skin tones and different levels of access to specialized care.
|
|
Educational Objectives
|
At the conclusion of this activity, participants should be able to demonstrate improved ability to:
- Examine the experiences of pediatric patients and their caregivers in managing moderate-to-severe AD
- Outline evidence-based treatment recommendations in pediatric AD
- Assess regional opportunities within managed care to address factors that contribute to healthcare disparities in the care and treatment of pediatric patients with AD
- Analyze regional trends that inform strategic decision-making to improve managed care policies for AD treatments within respective organizations
- Explore collaborative strategies for the implementation of equitable drug coverage policies for pediatric AD treatments
|
|
Agenda
|
Date and Time
Wednesday, July 17, 2024
6:00 PM - 6:30 PM PT - Registration and Reception
6:30 PM - 8:30 PM PT - Dinner and Presentation
NINE-TEN Restaurant & Bar
910 Prospect St.
La Jolla, CA 92037
Dinner and drinks provided by Impact Education, LLC.
|
Pediatric Experience with Moderate-to-Severe AD
Evidence-Based Treatment of Moderate-to-Severe AD in Children
- Disease overview
- Treatments and key considerations in Moderate-to-Severe AD
|
Health Inequities in Children with AD
- Factors Contributing to Healthcare Disparities in Children with AD
|
Moderated California-Region Panel Discussion
- Exploring Regional Perspectives on Pediatric AD Leveraging Regional Trends for Strategic Decision-Making in Managed Care
- Collaboration and Equitable Drug Coverage Policies for Pediatric AD Treatments
- Regional Initiatives to Address Health Disparities in Pediatric Patients
|
|
Accreditation Information
|
|
Joint Accreditation Statement |
 |
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE), the National Eczema Association (NEA) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
|
|
Physician Continuing Education
PACE designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|
Continuing Pharmacy Education
PACE designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
UAN: JA4008073-999-24-164-L01-P
Type of Activity: Application
|
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.
|
Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Fee Information
There is no fee for this educational activity.
|
|
